“ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic Covid-19 in this interim analysis of ongoing clinical trials,” the Lancet said.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3qBVg5c
via IFTTT
0 comments:
Post a Comment